IMNN — Imunon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 749647 ·
Last close
$1.07
Market Cap
$6.00M
52W High
$5.39
52W Low
$1.04
ADV30
129,634
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -4,306,552 | -4,249,022 | 8,018,713 | 4,794,070 | 4,659,082 |
| Dec 2025 | 0 | — | -4,261,703 | -4,222,850 | 12,288,116 | 8,781,059 | 5,226,240 |
| Sep 2025 | 0 | — | -3,475,828 | -3,429,124 | 8,987,733 | 5,250,929 | 4,906,009 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,034,749
Investing CF
$-20,920
Financing CF
$16,977,983
CapEx
$-295,479
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-7.02
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-425,547,094
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-14,811,947
Pretax Income TTM
$-14,641,555
Interest Exp TTM
$0
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -14,650,694 | -14,495,028 | 12,288,116 | 5,226,240 | 7,061,876 | -13,896,624 |
| Dec 2024 | 0 | -19,132,446 | -18,620,242 | 9,717,364 | 5,473,066 | 4,244,298 | -18,854,970 |
| Dec 2023 | 0 | -21,030,430 | -19,514,977 | 21,918,069 | 8,530,427 | 13,387,642 | -19,022,148 |
| Dec 2022 | 500,000 | -24,921,565 | -35,898,234 | 43,975,894 | 14,648,028 | 29,327,866 | -23,096,895 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-14,641,555
OpCashFlow TTM
—
Assets (Latest)
$8,018,713
Forward EPS
$-1.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INBP | INTEGRATED BIOPHARMA INC | $5.90M | $0.19 | — |
| GELS | Gelteq Ltd | $5.88M | $0.55 | — |
| KALA | KALA BIO, Inc. | $5.74M | $0.30 | — |
| INNPF | INNOCAN PHARMA Corp | $6.30M | $1.40 | — |
| MDCX | Medicus Pharma Ltd. | $6.44M | $0.10 | — |
News headlines (Yahoo Finance, 1h cache)
IMUNON to Participate in Upcoming Investor Conferences
2026-10-08 13:00 · Yahoo
IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer
2026-10-01 15:40 · Yahoo
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026-09-24 12:05 · Yahoo
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
2026-09-22 12:05 · Yahoo
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
2026-09-10 13:30 · Yahoo
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
2026-09-09 12:30 · Yahoo
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
2026-08-26 12:30 · Yahoo
IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial
2026-08-19 12:10 · Yahoo
Imunon (IMNN) Q2 2026 Earnings Call Transcript
2026-08-12 02:12 · Yahoo
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
2026-08-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.